TT
The startup has developed an antibody-based therapeutics platform that utilizes mass spectrometry and machine learning to identify tumor-specific protein modifications that contribute to cancer progression. This technology enables the creation of targeted antibody drugs that minimize damage to healthy tissues while effectively treating tumors.
Updated 2 months ago
Funding
$6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ATFunding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup has developed an antibody-based therapeutics platform that utilizes mass spectrometry and machine learning to identify tumor-specific protein modifications that contribute to cancer progression. This technology enables the creation of targeted antibody drugs that minimize damage to healthy tissues while effectively treating tumors.